Patent ID: 11911513
Assignee: SHANGHAI WD PHARMACEUTICAL CO., LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 6:
7. The method of claim 6, wherein in the extended release platform, when the drug-containing layer is composed of levodopa, carbidopa, microcrystalline cellulose, mannitol, citric acid, sodium hydroxypropyl methyl cellulose and magnesium stearate, the weight percentage of levodopa is 40%, the weight percentage of carbidopa is 10.8%, the weight percentage of microcrystalline cellulose is 20%, the weight percentage of mannitol is 18.7%, the weight percentage of citric acid is 5%, the weight percentage of hydroxypropyl methyl cellulose sodium is 5%, and the weight percentage of magnesium stearate is 0.5%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, microcrystalline cellulose, hydroxypropyl methyl cellulose and magnesium stearate, and the weight percentage of the levodopa is 38%, the weight percentage of microcrystalline cellulose is 50%, the weight percentage of hydroxypropyl methyl cellulose is 10%, and the weight percentage of magnesium stearate is 2%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, carbidopa, mannitol, citric acid and magnesium stearate, the weight percentage of the levodopa is 19.5%, and the weight percentage of carbidopa is 20%, the weight percentage of mannitol is 50%, the weight percentage of citric acid is 10%, and the weight percentage of magnesium stearate is 0.5%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, carbidopa, hydroxypropyl cellulose, mannitol, citric acid and magnesium stearate, the weight percentage of the levodopa is 40%, the weight percentage of carbidopa is 10.8%, the weight percentage of hydroxypropyl cellulose is 31%, the weight percentage of mannitol is 12.7%, and the weight percentage of citric acid is 5%, the weight percentage of the magnesium stearate is 0.5%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, carbidopa, hydroxypropyl cellulose, mannitol, citric acid and povidone K30, the weight percentage of levodopa is 40%, the weight percentage of carbidopa is 10.8%, the weight percentage of hydroxypropyl cellulose is 31%, the weight percentage of mannitol is 12.7%, and the weight percentage of citric acid is 5%, the weight percentage of povidone K30 is 0.5%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, hydroxypropyl cellulose, mannitol, povidone K30, magnesium stearate, mint flavor and aspartame, the weight percentage of levodopa is 45%, the weight percentage of hydroxypropyl cellulose is 31%, the weight percentage of mannitol is 16%, the weight percentage of povidone K30 is 5%, the weight percentage of the magnesium stearate is 1%, the weight percentage of the mint flavor is 1%, and the weight percentage of the aspartame is 1%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, mannitol, povidone K30, and magnesium stearate, the weight percentage of levodopa is 70%, the weight percentage of mannitol is 9%, the weight percentage of povidone K30 is 20%, and the weight percentage of magnesium stearate is 1%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, carbidopa, hydroxypropyl cellulose, mannitol, aspartame and magnesium stearate, the weight percentage of levodopa is 20%, the weight percentage of carbidopa is 20%, the weight percentage of hydroxypropyl cellulose is 50%, the weight percentage of mannitol is 4%, and the weight percentage of aspartame is 5%, the weight percentage of magnesium stearate is 1%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, hydroxypropyl cellulose, mannitol, povidone K30, magnesium stearate, and aspartame, the weight percentage of levodopa is 45%, the weight percentage of the hydroxypropyl cellulose is 31%, the weight percentage of the mannitol is 16%, the weight percentage of the povidone K30 is 5%, the weight percentage of magnesium stearate is 1%, the weight percentage of the mint flavor is 1%, and the weight percentage of aspartame is 1%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, hydroxypropyl cellulose, mannitol, povidone K30, magnesium stearate and aspartame, the weight percentage of levodopa is 45%, the weight percentage of the hydroxypropyl cellulose is 31%, the weight percentage of the mannitol is 17%, the weight percentage of the povidone K30 is 5%, the weight percentage of magnesium stearate is 1% and the weight percentage of aspartame is 1%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, hydroxypropyl cellulose, mannitol, povidone K30, magnesium stearate, mint flavor and aspartame; the weight percentage of the levodopa is 45%, the weight percentage of the hydroxypropyl cellulose is 31%, the weight percentage of the mannitol is 12%, and the weight percentage of the povidone K30 is 5%, the weight percentage of the mint flavor is 5%, the weight percentage of aspartame is 1%, and the weight percentage of magnesium stearate is 1%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, hydroxypropyl cellulose, mannitol, magnesium stearate, mint flavor and aspartame, the weight percentage of the levodopa is 62.5%, the weight percentage of the hydroxypropyl cellulose is 31%, the weight percentage of the mannitol is 4.5%, the weight percentage of the mint flavor is 0.1%, the weight percentage of aspartame is 0.9% and the weight percentage of magnesium stearate is 1%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the drug-containing layer is composed of levodopa, hydroxypropyl cellulose, mannitol, magnesium stearate, mint flavor and aspartame, the weight percentage of the levodopa is 46.9%, the weight percentage of the hydroxypropyl cellulose is 31%, the weight percentage of the mannitol is 20.1%, the weight percentage of the mint flavor is 0.1%, the weight percentage of aspartame is 0.9%, the weight percentage of magnesium stearate is 1%, wherein the weight percentage is the weight percentage of each component of the drug-containing layer.